bioAffinity Technologies partners with Pictor to develop asthma/COPD diagnostics

bioAffinity Technologies, Inc.

Collaboration integrates bioAffinity's flow cytometry with Pictor's targeted proteomic platform for lung inflammation tests.
Tests aim to match asthma/COPD patients with personalized treatments; asthma/COPD affect 40M Americans and 650M worldwide.
Global asthma/COPD therapeutics market projected to exceed $108B in 2026 and $155B by 2030.
bioAffinity will own IP for tests developed; Pictor retains its platform IP and owns new platform inventions.
Tests initially offered as Laboratory Developed Tests under CLIA; no financial terms disclosed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.